Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 25, 2026

COSW Sells Away Costco’s Upside Each Week to Fund Its Distributions

View original at finance.yahoo.com
“with net income rising 13.8% to $2.035 billion”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analyst consensus price target for Costco is $1,067

    60% confidence

  • Costco's fundamental case for continued appreciation is strong

    60% confidence

  • Analyst consensus price target for Costco is $1,067, above current levels

    60% confidence

  • Analyst consensus price target for Costco is $1,067

    60% confidence

  • COSW's income thesis depends on implied volatility levels that compress during calm markets

    60% confidence

  • COSW's income thesis depends on implied volatility levels that compress during calm markets

    60% confidence

  • COSW targets 1.2 times (120%) of Costco's weekly total return while distributing income every week through an options-based structure

    60% confidence

  • Costco's strong valuation multiples mean momentum bursts create forgone capital gains that get redirected into weekly distributions rather than fund NAV appreciation

    60% confidence

  • Analyst consensus price target for Costco is $1,067, above current levels

    60% confidence

Data points we hold from this source

Walmart Inc. · pe ratio44 ratio
Walmart Inc. · ytd stock return10 percent
Walmart Inc. · ytd return10 percent
Costco Wholesale Corporation · ytd return13 percent
Costco Wholesale Corporation · ytd stock return13 percent
Costco Wholesale Corporation · analyst price target1067 USD
Costco Wholesale Corporation · pe ratio50 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
COSW Sells Away Costco’s Upside Each Week to Fund Its Distributions — Source | Via News | ViaNews Market